Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

Autor: Louis-Philippe Boulet, C Hultquist, D. Ukena, R. Aalbers, Stefano Centanni, IP Naya, A.I. Manjra, L. Fouquert, R. Scicchitano

Publikováno v: Current Medical Research and Opinion, 20(9), 1403-1418. Taylor & Francis Ltd

Objectives:This study evaluated the efficacy and safety of a novel asthma management strategy - budesonide/formoterol for both maintenance and symptom relief (Symbicort Single Inhaler Therapy*) - compared with a higher maintenance dose of budesonide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b42a7b004108f8bdeca21cf1a59a2a
https://doi.org/10.1185/030079904x2051

How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?

Autor: Kerwin EM; Clinical Trials Department, Altitude Clinical Consulting and Clinical Research Institute of Southern Oregon, Medford, OR, USA., Jones PW; GSK, Brentford, UK., Bjermer LH; Department of Clinical Sciences, Respiratory Medicine and Allergology, Lund University, Lund, Sweden., Maltais F; Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada., Boucot IH; GSK, Brentford, UK., Naya IP; GSK, Brentford, UK., Lipson DA; Respiratory Clinical Sciences, GSK, Collegeville, PA, USA.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Compton C; GSK, Brentford, UK., Tombs L; Precise Approach Ltd, Contingent Worker on Assignment at GSK, Stockley Park West, Uxbridge, UK., Vogelmeier CF; Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-Universität Marburg, Marburg, Germany.

Publikováno v: Chronic respiratory disease [Chron Respir Dis] 2023 Jan-Dec; Vol. 20, pp. 14799731231202257.

Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial.

Autor: Bjermer L; Respiratory Medicine and Allergology, Lund University, Lund, Sweden., Boucot IH; Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK., Maltais F; Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Canada., Kerwin EM; Clinical Research Institute of Southern Oregon, Medford, OR, USA., Naya IP; Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK., Tombs L; Precise Approach Ltd, contingent worker on assignment at GSK, Stockley Park West, Uxbridge, Middlesex, UK., Jones PW; Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK., Compton C; Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK., Lipson DA; Respiratory Clinical Sciences, GSK, Collegeville, PA, USA.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Vogelmeier CF; Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany.

Publikováno v: International journal of chronic obstructive pulmonary disease [Int J Chron Obstruct Pulmon Dis] 2021 Jun 28; Vol. 16, pp. 1939-1956. Date of Electronic Publication: 2021 Jun 28 (Print Publication: 2021).

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.

Autor: Han MK; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA., Criner GJ; Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA., Dransfield MT; Lung Health Center, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Halpin DMG; Medical School, College of Medicine and Health, University of Exeter, Exeter, UK., Jones CE; GSK, Research Triangle Park, NC, USA., Kilbride S; GSK, Uxbridge, UK., Lange P; Section of Epidemiology, Dept of Public Health, University of Copenhagen, Copenhagen, Denmark.; Medical Dept, Herlev Gentofte Hospital, Herlev, Denmark., Lettis S; GSK, Uxbridge, UK., Lipson DA; GSK, Collegeville, PA, USA.; Pulmonary, Allergy and Critical Care Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Lomas DA; UCL Respiratory, University College London, London, UK., Martin N; GSK, Brentford, UK.; Institute for Lung Health, University of Leicester, Leicester, UK., Martinez FJ; NewYork-Presbyterian/Weill Cornell Medicine, New York, NY, USA., Wise RA; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Naya IP; GSK, Brentford, UK.; These authors contributed equally., Singh D; Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.; These authors contributed equally.

Publikováno v: ERJ open research [ERJ Open Res] 2021 Mar 08; Vol. 7 (1). Date of Electronic Publication: 2021 Mar 08 (Print Publication: 2021).

Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial.

Autor: Vogelmeier CF; Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-Universität Marburg, Germany.; Member of the German Centre for Lung Research (DZL), Baldingerstraße, Marburg 35043, Germany., Kerwin EM; Clinical Research Institute of Southern Oregon, Medford, OR, USA., Bjermer LH; Respiratory Medicine and Allergology, Lund University, Lund, Sweden., Tombs L; Precise Approach Ltd, Contingent Worker on Assignment at GSK, Stockley Park West, Uxbridge, Middlesex, UK., Jones PW; GSK, Brentford, Middlesex, UK., Boucot IH; GSK, Brentford, Middlesex, UK., Naya IP; GSK, Brentford, Middlesex, UK.; RAMAX Ltd., Bramhall, Cheshire, UK., Lipson DA; Respiratory Clinical Sciences, GSK, Collegeville, PA, USA.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Compton C; GSK, Brentford, Middlesex, UK., Barnes N; GSK, Brentford, Middlesex, UK., Maltais F; Centre de Pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Québec, Canada.

Publikováno v: Therapeutic advances in respiratory disease [Ther Adv Respir Dis] 2020 Jan-Dec; Vol. 14, pp. 1753466620968500.